Jasper Therapeutics, Inc. (JSPR) Stock Price & Analysis
Jasper Therapeutics, Inc. (JSPR) fell 5.58% to USD 0.69 as of July 25, 2026 at 06:54 UTC, according to Nexqual real-time market data.
JSPR last closed at USD 0.73; the session ranged USD 0.68–0.74 on volume of 665,162 shares. Market capitalization is $22.91M, with a 52-week range of USD 0.32–3.25 (NCM). Source: Nexqual, July 25, 2026 at 06:54 UTC.
Key Statistics (as of July 25, 2026 at 06:54 UTC)
| Price | USD 0.69 |
|---|---|
| Change | ▼ 5.58% (down) |
| Previous Close | USD 0.73 |
| Open | USD 0.7 |
| Day Range | USD 0.68 – 0.74 |
| 52-Week Range | USD 0.32 – 3.25 |
| Volume | 665,162 shares |
| Market Cap | $22.91M |
| Exchange | NCM |
Technical Analysis (JSPR)
Nexqual's technical model rates JSPR "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:54 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.1 (neutral) |
| vs SMA50 | Above (USD 0.63) |
| MACD | 0.05 (positive) |
Analyst Ratings (JSPR)
Wall Street analysts rate JSPR "None" based on 3 analysts, with a mean price target of USD 9.17 (range USD 1.5–20), per Nexqual as of July 25, 2026 at 06:54 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 9.17 |
| High Target | USD 20 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 2 / 3 / 0 |
Earnings (JSPR)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.55 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.38 vs est -0.54 ▲ beat |
| 2025-12-31 | USD -0.54 vs est -0.82 ▲ beat |
| 2025-09-30 | USD -1.25 vs est -1.29 ▲ beat |
| 2025-06-30 | USD -1.74 vs est -1.33 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
Financials & Fundamentals (JSPR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -244.21% |
| Debt / Equity | 22.27 |
| Current Ratio | 2.26 |
| Total Cash | $14.14M |
| Total Debt | $757,000 |
| Free Cash Flow | $-42.13M |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
Financial Health Score (JSPR)
Nexqual rates Jasper Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 06:54 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$69M |
| Efficiency | Critical — ROE -244%, ROA -112.2% |
Ownership (JSPR)
| Insider Ownership | +1.00% |
|---|---|
| Institutional Ownership | +47.62% |
| Shares Outstanding | 33.27M |
| Float | 23.31M |
| Short % of Float | +6.05% |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
Leadership (JSPR)
Jasper Therapeutics, Inc. is led by Thomas G. Wiggans (age 73), Executive Chairman, per Nexqual as of July 25, 2026 at 06:54 UTC.
| Executive Chairman | Thomas G. Wiggans (age 73) |
|---|---|
| Co-Founder, Member of Scientific Advisory Board & Director | Judith Anne Shizuru (age 69) |
| CFO & Corporate Secretary | Herbert C. Cross (age 53) |
Major Backers & Investors (JSPR)
Notable institutional backers of Jasper Therapeutics, Inc. include Velan Capital Investment Management LP, Millennium Management, Acorn Capital Advisors, LLC , according to Nexqual as of July 25, 2026 at 06:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Velan Capital Investment Management LP | 9.53% |
| Millennium Management | 5.77% |
| Acorn Capital Advisors, LLC | 5.04% |
| Kingdon Capital Management LLC | 4.83% |
| Morgan Stanley | 4.76% |
| Rock Springs Capital Management, LP | 3.93% |
| Carlyle Group Inc. | 3.81% |
| Boothbay Fund Management, LLC | 2.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.38% |
Source: Nexqual, July 25, 2026 at 06:54 UTC.
From Jasper Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Patent Application Serial Number 12/447,634 (publication number US 2010/0226927 Al) and know-how for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated.    Intellectual Property   Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates and other discoveries, inventions, trade secrets and know-how that are critical to our business operations.
- It also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights.
Partnerships
- We expect to continue to broaden our pipeline with additional mast cell indications.    We have an exclusive license agreement with Amgen Inc. ("Amgen") for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide.
- The issued U.S. patents would be expected to expire in 2027, absent any applicable patent term extensions.   License Agreement with Stanford   In March 2021, we entered into an exclusive license agreement with respect to the use of briquilimab from the Stanford Office of Technology Licensing to license U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| PALI | Palisade Bio, Inc. | USD 1.95 | ▲ 2.63% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.55 | ▲ 0.79% |
| CNTX | Context Therapeutics Inc. | USD 0.61 | ▲ 0.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:54 UTC. This page is informational and not investment advice.